Active substanceProtamine sulfateProtamine sulfate
Similar drugsTo uncover
  • Protagem®
    solution in / in 
    EKOFARMPLUS, CJSC     Russia
  • Protamine
    solution in / in 
    BINERGIYA, CJSC     Russia
  • Protamine-Ferein
    solution in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Protamine sulfate
    solution in / in 
    ELLARA, LTD.     Russia
  • Protamine sulfate
    solution for injections 
    Galenika ad.     Serbia
  • Protamine sulfate
    solution in / in 
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    Active substance: protamine sulfate 10 mg;

    auxiliary substance: water for injection up to 1 ml.

    Description:Transparent, colorless or with a yellowish tinge of liquid.
    Pharmacotherapeutic group:hemostatic agent
    ATX: & nbsp

    V.03.A.B   Antidotes

    Pharmacodynamics:

    Heparin antagonist. Inactivates heparin by electrostatic interaction with it.

    Protamine is a peptide obtained from mature testes of various fish in the form of sulfate or chloride, and is used to neutralize the anti-coagulant effect of heparin. Approximately 67% of the amino acid composition of protamine is arginine, which makes it a strongly alkaline polycationic substance with a molecular weight of 4,500 Da. Multiple positively charged protamine chains are connected to negatively charged DNA groups.

    In vitro When a heparin is added to the protamine, a stable precipitate forms due to ionic interactions. The protamine molecule contains two active centers, one of which neutralizes heparin and the other has moderate anticoagulant activity, regardless of heparin. The activity of the preparation is determined by the biological method according to the ability to neutralize the anti-convulsant action of heparin on bovine or sheep plasma in vitro, in the presence of an excess of calcium chloride. Activity is expressed in units of action (ED). In 1 ml of the drug solution should contain at least 750 units. 1 mg (75 U) of protamine sulfate neutralizes approximately 85 units of sodium heparin.

    Effective in some types of hemorrhages associated with heparin-like disorders of blood clotting.

    Although the drug is considered a heparin antagonist, in large doses, it is itself capable of providing an anticoagulant effect, which is sometimes mistakenly assessed as a result of insufficient neutralization of heparin.

    Pharmacokinetics:

    With intravenous administration, the effect occurs instantaneously ("on the needle") and lasts about 2 hours. Protamine sulfate is excreted from the body mainly through the kidneys and to a lesser extent - through the liverwith bile. Together with heparin forms an inactive complex, the half-life of which is 24 minutes. Protamine sulfate is inactivated in the plasma by enzymes, whereas the protamine-heparin complex appears to break down in adipose tissue with the release of heparin.

    Indications:

    - Bleeding caused by an overdose of heparin;

    - before surgery in patients who take heparin with a therapeutic purpose;

    - after operations on the heart and blood vessels with extracorporeal circulation;

    - hypergeparinemia.

    Contraindications:

    - Hypersensitivity to the components of the drug;

    - idiopathic or congenital hyperheparinemia (in such cases, the drug is not effective and may increase bleeding);

    - severe arterial hypotension;

    - thrombocytopenia;

    - insufficiency of the adrenal cortex;

    - patients with insulin containing Protamine sulfate, as well as other medicines containing Protamine sulfate;

    - allergic reactions to fish in the anamnesis.

    The experience of medical use in children is limited.

    Carefully:

    Perhaps the manifestation of cross-sensitivity in diabetic patients receiving protamine-zinc insulin.Patients who took protamine-zinc insulin for the treatment of diabetes mellitus may have anaphylactic reactions to Protamine sulfate.

    Pregnancy and lactation:

    Controlled clinical and preclinical studies of the effect of the drug on pregnancy have not yet been conducted. Under these circumstances, the drug can be given to pregnant women only if the expected positive effect for the mother exceeds the possible risk to the fetus.

    It is not known whether protamine penetrates into breast milk. During the use of the drug should stop breastfeeding.

    Dosing and Administration:

    Intravenously struino slowly or drip under the control of blood coagulability.

    When an overdose of heparin is injected at a rate of 1 ml (10 mg) of protamine sulfate solution for 2 minutes. If necessary, the injections are repeated at intervals of 15-30 minutes, the total dose is usually 5 ml (50 mg) of the solution.

    The maximum dose is 150 mg / h.

    In case of bleeding, the daily dose is 5-8 mg / kg; intravenously drip in 2 divided doses at intervals of 6 hours.

    The dose of the drug depends on the method of administration of heparin. The calculated dose of the drug is dissolved in 300-500 ml of 0.9% sodium chloride solution.

    With bolus injections of heparin, the dose of protamine sulfate decreases depending on the time elapsed from the administration of heparin, since the latter is continuously removed from the body.

    Time elapsed since

    injections of heparin

    The dose of protamine sulfate in

    calculated per 100 ME heparin

    15-30 minutes

    1.2-1.3 mg

    30-60 minutes

    0.5-0.75 mg

    Over 2 hours

    0.25-0.375 mg

    2. If heparin was injected intravenously, it is necessary to stop its infusion and introduce 25-30 mg of protamine sulfate.

    3. With subcutaneous and intramuscular injections of heparin, the dose of protamine sulfate is 1.2-1.3 mg per 100 ME heparin.

    The first 25-50 mg of protamine sulphate should be administered intravenously slowly, and the remaining dose - intravenously drip during 8-16 hours. Probably fractional administration of protamine sulfate, which requires control of activated partial thromboplastin time (APTT). For example, if administered subcutaneously 20000 ME heparin, after 2 hours there is a resorption of heparin, from complexes with protamine to 3333 ME heparin, in this regard, the next dose of protamine sulfate is 33 mg.

    4. In the case of using extracorporeal circulation during surgery, the dose of protamine sulfate is 1.2-1.3 mg per 100 ME heparin.When determining the dose of protamine, it is necessary to take into account the route of administration of heparin.

    The maximum duration of treatment is 3 days.

    With hypergeparinemia associated with extracorporeal circulation, the dose of the drug can be increased; in these cases, the solution is administered dropwise. Protamine sulfate is used to neutralize low molecular weight heparins (LMWH), but it is not able to completely eliminate their antithrombotic activity: 1 mg of protamine sulfate neutralizes 100 units of anti-IIbut of activity and not more than 60% of anti-Xa activity of low molecular weight heparins. When choosing a dose of protamine sulfate, it is necessary to take into account the amount of introduced low-molecular heparin, the route of its administration, the pharmacokinetics of the drug used, and the time elapsed after the last injection of low-molecular heparin.

    Introduce Protamine sulfate intravenously slowly (1 mg protamine sulfate per 100 anti-Xa ME recently introduced low-molecular-weight heparin) or as an infusion. 8 hours after intravenous drip of low molecular weight heparin, a half dose of protamine sulfate can be used, after 12 hours Protamine sulfate most likely not required.Long-term preservation of the effect of low molecular weight heparin, which continues to come from the subcutaneous tissue, makes it justified to infuse a calculated dose of protamine sulfate for several hours or to repeat half-dose administration with persistent bleeding.

    Patients with renal and hepatic insufficiency

    In patients with mild to moderate renal insufficiency (CK> 30 mL / min and <60 mL / min), no dose reduction is required, in patients with severe renal insufficiency (CK <30 mL / min), the dose should be reduced by 25% .

    Use with caution in liver failure.

    Elderly people

    In elderly patients, dose adjustments are not required (except for patients with impaired renal function).

    Use in Pediatrics

    Safety and effectiveness of protamine sulfate in children have not been studied, so the drug is not used in this category of patients. There are no data on the use of the drug in children.

    Side effects:

    From the side of the cardiovascular system: lowering of blood pressure, bradycardia, pulmonary and systemic arterial hypertension, noncardiogenic pulmonary edema.

    From the respiratory system: bronchospasm.

    From the hemopoietic organs: neutropenia, thrombocytopenia.

    From the digestive system: nausea, vomiting.

    From the immune system: skin rash, itching, the development of anaphylactoid reactions, hypersensitivity reactions, anaphylactic shock (including fatal).

    From the musculoskeletal system: backache.

    Other: a feeling of heat, skin flushing, a feeling of lack of air (with an overly rapid introduction).

    Overdose:

    Can be accompanied by bleeding, tk. Protamine has its own anticoagulant activity.

    Treatment is symptomatic.

    Interaction:

    Protamine sulfate is an antagonist of low molecular weight heparins.

    Pharmaceutically incompatible with cephalosporins and penicillins.

    May increase the intensity and duration of action of nondepolarizing muscle relaxants.

    There is no data on the interaction with other drugs.

    Special instructions:

    The administration is carried out under the control of blood coagulability. Before the introduction, you should make sure the adequacy of the blood volume of the patient (hypovolemia increases the risk of collapse).

    Care should be taken when using protamine sulfate patients with a high risk of allergic reactions to the drug, since there is a risk of anaphylactic shock. Risk factors for such reactions may be allergy to fish, vasectomy, the use of protamine-zinc insulin in patients with diabetes mellitus or protamine for heparin inactivation. It is necessary to administer the drug in a specialized department that has the necessary equipment for emergency medical care.

    It is necessary to assess the benefit-risk relationship before protamine sulfate is used in patients with a heparin overdose, but without signs of bleeding.

    In patients who are reassigned Protamine sulfate it is necessary to monitor the blood coagulation system.

    Protamine sulfate has its own anticoagulant activity and can prolong the time of bleeding when applying excessive doses of the drug. Such bleeding can be controlled by prescribing heparin sodium until the thrombin time returns to the normal range.Perhaps the emergence of a "recoil phenomenon" with the development of bleeding, despite adequate inhibition of heparin sodium activity.

    Effect on the ability to drive transp. cf. and fur:

    Given the possible side effects of the drug, care should be taken when driving vehicles and carrying out potentially hazardous activities.

    Form release / dosage:Solution for intravenous administration, 10 mg / ml.
    Packaging:

    5 ml in bottles with a capacity of 10 ml of glass, hermetically sealed with rubber stoppers, crimped with aluminum caps or combined caps made of aluminum and plastic.

    2 or 5 ml into neutral glass ampoules.

    For 5 vials or ampoules are placed in a contour mesh package of polyvinyl chloride film.

    Five vials or ampoules are placed in a contour mesh box made of a polyvinylchloride film and foil of an aluminum printed lacquered or flexible package based on aluminum foil and packaging material.

    For 1, 2 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    For 5, 10 bottles together with the instruction for use are placed in a pack with an insert with cells for bottles in 1 or 2 rows of cardboard.

    For 5, 10 ampoules, together with the instruction for use, are placed in a pack with an insert with cells for ampoules in 1 or 2 rows of cardboard

    Packing for hospitals

    For 50, 108 bottles together with an equal number of instructions for use are placed in a box of cardboard.

    For 10 contiguous cell packs with vials or 10, 100, 200 contour packs with ampoules together with an equal number of instructions for use are placed in a box of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of 4 to 25 ° C.

    Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007016/08
    Date of registration:02.09.2008
    The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspBRYNTSALOV-A, CJSCBRYNTSALOV-A, CJSC
    Information update date: & nbsp09.09.2015
    Illustrated instructions
      Instructions
      Up